secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2024-10-17T23:59:59+00:00
Accession:  0001104659-24-109521
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx reprices CEO's 196,880 options to $0.0001, accelerates vesting
--------------------------------------------------------------------

- CEO Sumit Aggarwal holds 196,880 options with weighted avg exercise price $0.90 repriced to $0.0001.
- Options granted under 2018 Equity Incentive Plan; exercisable in full as of Oct 16, 2024 regardless of vesting.
- New exercise price set to $0.0001, the closing OTC price on the repricing date.
- Option repricing approved by Board on Oct 16, 2024; amendment approved by Compensation Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465924109521/0001104659-24-109521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465924109521/tm2426349d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-109521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer